№ lp_1_2_22248
File format: docx
Character count: 32740
File size: 143 KB
Version:
HNY v2.0
Replaces version:
HNY v1.0
Clinical content last reviewed:
October 2023
Next review date:
September 2028
Date published:
1st October 2025
Approved for use by Humber and North Yorkshire ICB:
1st October 2025
Local content added:
September 2025
Note:
Licensed indications updated to reflect currently available products
Background:
Azathioprine and mercaptopurine are disease modifying anti-rheumatic drugs (DMARDs). They are used as immunosuppressant anti-metabolites either alone or in combination with other agents (usually corticosteroids).
Type:
Shared Care Protocol
Region / city:
Humber and North Yorkshire
Organization / institution:
Humber and North Yorkshire ICB
Author:
RDTC
Target audience:
NHS healthcare professionals
Period of validity:
Until September 2028
Approval date:
1st October 2025
Date of last review:
October 2023
Date of next review:
September 2028
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Version:
NENC v1.0
Date published:
12th December 2024
Changes since previous version:
Adapted from RDTC v1.2 published 26th November 2024
Planned review date:
March 2026
Licensed and agreed off-label indications:
Azathioprine, Mercaptopurine
Specialist:
NHS healthcare professionals
Target audience:
Healthcare professionals in adult services
Indication:
Auto-immune chronic active hepatitis, Behçet’s disease, inflammatory bowel disease, and others
Type of document:
Shared Care Protocol
Clinical guidelines:
BNF, NICE, BSR, BHPR
Local variations:
Gateshead
Period of use:
Ongoing, review by March 2026
Background:
Azathioprine and mercaptopurine as disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory conditions.
Version:
NENC v1.0
Date published:
12th December 2024
Changes since previous version:
Adapted from RDTC v1.2 published 26th November 2024
Planned review date:
March 2026
Licensed and agreed off-label indications:
Azathioprine, Mercaptopurine
Specialist:
NHS healthcare professionals
Target audience:
Healthcare professionals in adult services
Indication:
Auto-immune chronic active hepatitis, Behçet’s disease, inflammatory bowel disease, and others
Type of document:
Shared Care Protocol
Clinical guidelines:
BNF, NICE, BSR, BHPR
Local variations:
Gateshead
Period of use:
Ongoing, review by March 2026
Background:
Azathioprine and mercaptopurine as disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory conditions.
Jurisdiction:
Commonwealth of Massachusetts
Year:
2016
Update date:
July 2016
Document type:
Application form
Purpose:
Designer qualification and submission for public projects
Applicable entities:
Municipalities and public agencies not within DSB jurisdiction
Issuing authority:
Commonwealth of Massachusetts
Subject matter:
Public procurement, designer selection
Intended applicants:
Design firms and joint ventures
Regulatory context:
Massachusetts public design and construction procurement
Year:
2016
Region / City:
Commonwealth of Massachusetts
Topic:
Designer Application
Document Type:
Application Form
Organization / Institution:
Massachusetts Public Agencies
Author:
Not specified
Target Audience:
Municipalities, Public Agencies
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
July 2016
Year:
2020
Region / City:
USA
Topic:
Biosafety, Laboratory Systems, Public Health
Document Type:
Email Communication
Organization / Institution:
Centers for Disease Control and Prevention (CDC)
Author:
Division of Laboratory Systems, CDC
Target Audience:
Laboratory professionals, clinicians, and leadership in rural and community hospitals
Period of Action:
Not specified
Approval Date:
Not specified
Date of Modifications:
Not specified
Year:
2016
Region / City:
Massachusetts
Topic:
Designer Application for Municipalities and Public Agencies
Document Type:
Application Form
Organization / Institution:
Commonwealth of Massachusetts
Author:
Not specified
Target Audience:
Municipalities and Public Agencies
Effective Period:
Not specified
Approval Date:
Not specified
Date of Amendments:
Not specified
Year:
2026
Version:
NENC v2.0
Date published:
22 January 2026
Planned review date:
October 2027
Region:
North East and North Cumbria
Healthcare system:
NHS
Clinical area:
Neurology
Condition:
Amyotrophic lateral sclerosis
Medicine:
Riluzole
Document type:
Shared care protocol
Indication:
Extension of survival or time to mechanical ventilation in ALS
Target population:
Adults
Intended audience:
NHS healthcare professionals
Initiating authority:
Neurological specialist services
Regulatory reference:
NICE Technology Appraisal TA20
Prescribing setting:
Secondary to primary care transfer
Monitoring requirements:
Liver function tests, full blood count, urea and electrolytes
Route of administration:
Oral or enteral
Licensing status:
Licensed for ALS only
Year:
2024
Region / City:
Northwest Florida
Subject:
Environmental Resource Permitting, Stormwater Management
Document Type:
Handbook
Agency / Institution:
Florida Department of Environmental Protection, Northwest Florida Water Management District
Author:
Florida Department of Environmental Protection, Northwest Florida Water Management District
Target Audience:
Permit applicants, engineers, environmental consultants
Period of Validity:
N/A
Approval Date:
June 28, 2024
Date of Changes:
N/A
Year:
2025
Region / City:
Western Australia
Theme:
Utility services, roadworks
Document Type:
Application Form
Organization / Institution:
Main Roads WA
Author:
Main Roads WA
Target Audience:
Utility Service Providers, Local Government, Contractors
Period of Action:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Year:
2024
Region / city:
Humber and North Yorkshire ICB
Theme:
Hydroxychloroquine treatment protocol
Document type:
Clinical guideline
Organization / institution:
NHS
Author:
RDTC
Target audience:
NHS healthcare professionals
Effective period:
From the initiation date until March 2028
Approval date:
March 2025
Date of changes:
November 2023
Next review date:
March 2028
Year:
2025
Region / city:
Global
Thematic area:
Disability, Gender, Social Protection
Document type:
Report
Organization / institution:
UNICEF
Author:
UNICEF
Target audience:
Policymakers, planners, implementers, communities
Period of validity:
2024–2030
Approval date:
2024
Date of changes:
2024
Contextual description:
The document provides insights and tools for addressing the challenges and support systems related to children with disabilities and their families, focusing on gendered aspects and inclusive approaches in care and development.
Year:
2025
Region / City:
Geneva
Theme:
Intellectual Property, Indigenous Rights
Document Type:
Report
Organization / Institution:
World Intellectual Property Organization (WIPO)
Author:
Elifuraha Laltaika, Neva Collings
Target Audience:
Members of the Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore
Period of Effect:
2020-2021
Approval Date:
March 19, 2025
Amendment Date:
N/A
Note:
Year
Subject:
Organic certification and handling procedures
Document Type:
Organic certification questionnaire
Organization:
ACO (Australian Certified Organic)
Author:
ACO
Target Audience:
Organic operators
Effective Period:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Note:
Year
Region / City:
Singapore
Topic:
Hazardous Chemicals Transportation
Document Type:
Emergency Response Plan
Year:
2021
Region / city:
N/A
Subject:
Coaching and Mentoring
Document type:
Assessment Instructions
Organization / institution:
Arema Academy
Author:
N/A
Target audience:
Learners enrolled in coaching and mentoring courses
Validity period:
N/A
Approval date:
N/A
Modification date:
N/A